Amylyx Pharmaceuticals Inc (AMLX)
1.93
+0.12
(+6.63%)
USD |
NASDAQ |
May 01, 16:00
1.93
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Net Income (TTM): 49.27M for Dec. 31, 2023
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 49.27M |
| September 30, 2023 | 1.836M |
| June 30, 2023 | -72.81M |
| March 31, 2023 | -148.95M |
| December 31, 2022 | -198.38M |
| Date | Value |
|---|---|
| September 30, 2022 | -184.02M |
| June 30, 2022 | -153.40M |
| March 31, 2022 | -121.26M |
| December 31, 2021 | -87.93M |
| September 30, 2021 | -68.18M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-198.38M
Minimum
Dec 2022
49.27M
Maximum
Dec 2023
-98.38M
Average
-104.59M
Median
Net Income (TTM) Benchmarks
| Cassava Sciences Inc | -97.22M |
| iRhythm Technologies Inc | -123.41M |
| Bristol-Myers Squibb Co | -6.148B |
| Moderna Inc | -4.714B |
| ACADIA Pharmaceuticals Inc | -61.29M |